Patients, especially women, experience a high degree of side effects from myasthenia gravis (MG) treatment, according to a U.K. survey examining real-world use of the medications. As steroid-sparing agents, mycophenolate mofetil (sold as CellCept) and methotrexate (sold as Trexall, among others) were less likely to be discontinued…
News
A woman with hard-to-treat generalized myasthenia gravis (gMG) who was seronegative, or tested negative for disease-driving self-directed antibodies, was successfully treated with off-label Vyvgart (efgartigimod alfa-fcab), as reported in a case study from Italy. According to researchers, this case provides evidence that limiting Vyvgart to MG patients with…
A traditional Chinese medicine practice that combines acupuncture and moxibustion, given along with standard treatments, may ease symptoms for people with myasthenia gravis (MG) more effectively than conventional medications alone. That’s according to “Acupuncture and moxibustion treatment for myasthenia gravis: A systematic review and meta-analysis,” which…
Vyvgart (efgartigimod) eased symptoms of generalized myasthenia gravis (gMG) for some patients in Japan and the therapy’s effects didn’t appear to be influenced by the type of MG-driving antibody each patient had, a new analysis shows. The study, “Therapeutic Responses to Efgartigimod for Generalized Myasthenia…
The initial treatment benefits of Soliris (eculizumab) were maintained after people with generalized myasthenia gravis (gMG) switched over to Ultomiris (ravulizumab-cwvz), a small real-world study confirmed. Most patients who completed a survey almost six months after switching said they preferred Ultomiris due to treatment convenience, lower frequency…
Butyric acid from gut bacteria, or supplementation with its salt form butyrate, could become potential treatments for myasthenia gravis (MG) by working to restore the function of immune cells that limit the production of disease-causing antibodies. That’s according to the findings of a new study in human cells and…
The 2024 National Patient Conference by the Myasthenia Gravis Foundation of America (MGFA) brought together more than 400 members of the myasthenia gravis (MG) community this week to educate participants about how to better manage their disease and raise awareness about treatments and clinical studies. “We are so…
Treatment with an oral version of salbutamol, the active ingredient of medications used for asthma and other respiratory conditions, may help ease symptoms in some people with MuSK-positive myasthenia gravis (MG), a small study reports. The study was published as a letter to the editor, titled “…
Many of the adults with generalized myasthenia gravis (gMG) who took part in ADAPT, a Phase 3 clinical study of Vyvgart (efgartigimod), and its open-label extension, ADAPT+, experienced minimal or no symptoms and a quality of life closer to that of healthy adults. While Vyvgart is approved to…
Ultomiris (ravulizumab) continues to be well tolerated and to keep symptoms of generalized myasthenia gravis (gMG) under control when used for more than three years, according to a final analysis of data from an open-label extension of the Phase 3 CHAMPION-MG trial. The data were presented by Tuan…
Recent Posts
- New study explores when MG patients can taper immunosuppressive therapy
- Thymus gland removal seen as effective option for late-onset MG
- A caregiver’s perspective on his wife’s health after breast reduction
- My twin loves junk food, but a veggie and fruit diet is helping him combat MG
- My secret book of survival in life with myasthenia gravis